Citadel Advisors’s BioLineRX BLRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-36,651
| Closed | -$104K | – | 13013 |
|
|
2025
Q4 | $104K | Buy |
36,651
+26,631
| +266% | +$92K | ﹤0.01% | 11605 |
|
|
2025
Q3 | $37.9K | Sell |
10,020
-4,934
| -33% | -$19.8K | ﹤0.01% | 12318 |
|
|
2025
Q2 | $68.3K | Buy |
+14,954
| New | +$55.3K | ﹤0.01% | 11608 |
|
|
2025
Q1 | – | Sell |
-383
| Closed | -$3.25K | – | 14505 |
|
|
2024
Q4 | $3.25K | Buy |
+383
| New | +$5.65K | ﹤0.01% | 14010 |
|
|
2024
Q1 | – | Sell |
-605
| Closed | -$30.3K | – | 14577 |
|
|
2023
Q4 | $38K | Sell |
605
-869
| -59% | -$53.8K | ﹤0.01% | 12057 |
|
|
2023
Q3 | $107K | Sell |
1,474
-3,845
| -72% | -$258K | ﹤0.01% | 10815 |
|
|
2023
Q2 | $339K | Buy |
+5,319
| New | +$295K | ﹤0.01% | 8772 |
|
|
2022
Q3 | – | Sell |
-569
| Closed | -$29K | – | 12631 |
|
|
2022
Q2 | $29K | Buy |
+569
| New | +$31.6K | ﹤0.01% | 12240 |
|
|
2021
Q4 | – | Sell |
-4,129
| Closed | -$430K | – | 13814 |
|
|
2021
Q3 | $451K | Buy |
4,129
+3,002
| +266% | +$356K | ﹤0.01% | 10127 |
|
|
2021
Q2 | $127K | Buy |
+1,127
| New | +$132K | ﹤0.01% | 12683 |
|
|
2021
Q1 | – | Sell |
-1,233
| Closed | -$124K | – | 13162 |
|
|
2020
Q4 | $124K | Buy |
+1,233
| New | +$108K | ﹤0.01% | 10078 |
|
|
2019
Q2 | – | Sell |
-56
| Closed | -$14K | – | 9174 |
|
|
2019
Q1 | $14K | Sell |
56
-41
| -42% | -$11.9K | ﹤0.01% | 9119 |
|
|
2018
Q4 | $26K | Buy |
+97
| New | +$46.7K | ﹤0.01% | 8660 |
|
|
2018
Q2 | – | Sell |
-22
| Closed | -$11K | – | 8822 |
|
|
2018
Q1 | $11K | Sell |
22
-14
| -39% | -$8.58K | ﹤0.01% | 8175 |
|
|
2017
Q4 | $24K | Buy |
36
+17
| +89% | +$11.2K | ﹤0.01% | 7800 |
|
|
2017
Q3 | $13K | Buy |
+19
| New | +$11.8K | ﹤0.01% | 7423 |
|
|
2017
Q2 | – | Sell |
-177
| Closed | -$102K | – | 7483 |
|
|
2017
Q1 | $102K | Buy |
177
+144
| +436% | +$92.7K | ﹤0.01% | 6854 |
|
|
2016
Q4 | $18K | Buy |
33
+6
| +22% | +$3.73K | ﹤0.01% | 7102 |
|
|
2016
Q3 | $19K | Buy |
+27
| New | +$14.4K | ﹤0.01% | 7063 |
|
|
2014
Q2 | – | Sell |
-54
| Closed | -$72K | – | 7963 |
|
|
2014
Q1 | $72K | Buy |
+54
| New | +$88.8K | ﹤0.01% | 6472 |
|
Other funds holding BLRX
XT
NRG
NA
Citadel Advisors's BLRX Position: Q1 2026 in Review
Citadel Advisors sold out of BioLineRX (BLRX) in Q1 2026, closing a stake of 36,651 shares — an estimated $104K sold.
Citadel Advisors first reported a position in BLRX in Q1 2014 and held it in 20 quarters. The position peaked at $451K in Q3 2021. 13 funds tracked by Wall St. Rank hold BLRX as of Q1 2026.
- Citadel Advisors reported no remaining BioLineRX position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 36,651 BioLineRX shares in Q1 2026, an estimated $104K.
- Citadel Advisors first reported a position in BioLineRX in Q1 2014 and held it in 20 quarters.
- Citadel Advisors's BioLineRX position peaked at $451K in Q3 2021.
- 13 funds tracked by Wall St. Rank held BioLineRX as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.